


RESEARCH ARTICLE

Lactobacillus paracasei GMNL-32 exerts a therapeutic effect on cardiac abnormalities in NZB/W F1 mice

Wei-Syun Hu^{1,2}*, Peramaiyan Rajendran³, Bor-Show Tzang⁴, Yu-Lan Yeh^{5,6}, Chia-Yao Shen⁷, Ray-Jade Chen⁸, Tsung-Jung Ho⁹, Viswanadha Vijaya Padma¹⁰, Yi-Hsing Chen¹¹*, Chih-Yang Huang^{3,9,12}*

1 School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, ROC, **2** Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, Taichung, Taiwan, ROC, **3** Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, ROC, **4** Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan, ROC, **5** Department of pathology, Changhua Christian Hospital, Changhua, Taiwan, ROC, **6** Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan, ROC, **7** Department of Nursing, Mei Ho University, Pingtung, Taiwan, ROC, **8** Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC, **9** Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan, ROC, **10** Department of Biotechnology, Bharathiar University, Coimbatore, India, **11** Research and Development Department, GenMont Biotech Incorporation, Tainan, Taiwan, ROC, **12** Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan, ROC

* These authors contributed equally to this work.
* cyhuang@mail.cmu.edu.tw



OPEN ACCESS

Citation: Hu W-S, Rajendran P, Tzang B-S, Yeh Y-L, Shen C-Y, Chen R-J, et al. (2017) *Lactobacillus paracasei* GMNL-32 exerts a therapeutic effect on cardiac abnormalities in NZB/W F1 mice. PLoS ONE 12(9): e0185098. <https://doi.org/10.1371/journal.pone.0185098>

Editor: Yi-Hsien Hsieh, Institute of Biochemistry and Biotechnology, TAIWAN

Received: June 20, 2017

Accepted: September 6, 2017

Published: September 21, 2017

Copyright: © 2017 Hu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work is supported by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019) and GenMont Biotech Incorporation, Taiwan. (1044E1). The funding organization provided support in the form of salaries for Y-H.C. and research materials (*L. paracasei* GMNL-32), but did not have any additional role in the study design, data collection and analysis, decision to

Abstract

Systemic lupus erythematosus (SLE) is a disease that mostly affects women. Accelerated atherosclerosis is a high-risk factor associated with SLE patients. SLE associated with cardiovascular disease is one of the most important causes of death. In this study, we demonstrated that *Lactobacillus paracasei* GMNL-32 (GMNL-32), a probiotic species, exhibits anti-fibrosis and anti-apoptotic effects on the cardiac tissue of NZB/WF1 mice. Female NZB/W F1 mice, a well-known and commonly used lupus-prone mouse strain, were treated with or without GMNL-32 administration for 12 weeks. Oral administration of GMNL-32 to NZB/WF1 mice significantly increased the ventricular thickness when compared to that of NZB/WF1 mice. Administration of GMNL-32 significantly attenuated the cardiac cell apoptosis that was observed in exacerbate levels in the control NZB/WF1 mice. Further, the cellular morphology that was slightly distorted in the NZB/WF1 was effectively alleviated in the treatment group mice. In addition, GMNL-32 reduced the level of Fas death receptor-related pathway of apoptosis signaling and enhanced anti-apoptotic proteins. These results indicate that GMNL-32 exhibit an effective protective effect on cardiac cells of SLE mice. Thus, GMNL-32 may be a potential therapeutic strategy against SLE associated atherosclerosis.